Last reviewed 2026-04-22 · How we verify

Eldecalcitol capsules

Eldecalcitol is an active vitamin D analog that binds to the vitamin D receptor to regulate calcium and phosphate metabolism and promote bone mineralization.

Eldecalcitol is an active vitamin D analog that binds to the vitamin D receptor to regulate calcium and phosphate metabolism and promote bone mineralization. Used for Osteoporosis, Metabolic bone disease.

At a glance

Mechanism of action

Eldecalcitol is a synthetic analog of 1,25-dihydroxyvitamin D3 that activates the vitamin D receptor (VDR) in target tissues including bone, intestine, and kidney. By binding to VDR, it enhances intestinal calcium and phosphate absorption, suppresses parathyroid hormone secretion, and promotes osteoblast differentiation and bone formation. This mechanism makes it effective in treating osteoporosis and other metabolic bone diseases.

Approved indications

• Osteoporosis
• Metabolic bone disease

Common side effects

• Hypercalcemia
• Hyperphosphatemia
• Nausea
• Constipation

Key clinical trials

• Study on the Intervention Effect of Denosumab on High-Risk Patients With Osteoporotic Fractures in Type 2 Diabetes (NA)
• Clinical Intervention of Idecalcitol Combined With Whey Protein Powder and Exercise for Sarcopenia (PHASE4)
• Eldecalcitol and Calcitriol in Postmenopausal Women With Low Bone Mineral Density or Mild Osteoporosis (PHASE4)
• A Study on the Prevention and Treatment of GIOP With Eldecalcitol (PHASE4)
• Post-Marketing Drug Intensive Monitoring Surveillance of EDIROL in Patients With Postmenopausal Osteoporosis
• Bioequivalence Study of Eldecalcitol Soft Capsule in Healthy Chinese Subjects (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.